Christopher Mitchell, MD
Urology · Wilmington, DENPI 1124274105
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Intuitive Surgical at 27.6% of the total. Among urology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $149.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Richard Wolf Medical Instruments Corp.$4K
- AstraZeneca$2K
- Janssen Scientific Affairs, LLC$2K
- Dendreon Pharmaceuticals LLC$1K
- Neotract Inc.$1K
- plus $4K from 27 others
What the payments were for
- Consulting fees$9,28749%
- Travel & lodging$6,32934%
- Food & beverage$3,14117%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $5,197 |
| Richard Wolf Medical Instruments Corp. | 4 | $4,134 |
| AstraZeneca | 5 | $1,712 |
| Janssen Scientific Affairs, LLC | 2 | $1,555 |
| Dendreon Pharmaceuticals LLC | 3 | $1,375 |
| Neotract Inc. | 7 | $1,041 |
| Bayer | 2 | $944 |
| Urogen Pharma, Inc. | 21 | $721 |
| Johnson & Johnson(2 entities) | 4 | $243 |
| Pfizer | 9 | $212 |
| Merck | 7 | $170 |
| Myriad Genetic Laboratories, Inc. | 3 | $156 |
| Telix Pharmaceuticals | 7 | $153 |
| Tolmar, Inc. | 1 | $151 |
| Ferring Pharmaceuticals Inc. | 1 | $131 |
| Myovant Sciences Inc. | 6 | $108 |
| Progenics Pharmaceuticals, Inc. | 4 | $98 |
| Baxter Healthcare | 3 | $97 |
| Palette Life Sciences, Inc. | 3 | $84 |
| Astellas Pharma US Inc | 4 | $68 |
| AbbVie(2 entities) | 3 | $61 |
| Tempus AI, Inc | 2 | $57 |
| Civco Medical Instruments | 1 | $54 |
| Novartis | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Dentsply IH AB | 1 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $32 |
| Axonics, Inc. | 1 | $31 |
| Blue Earth Diagnostics | 1 | $27 |
| BD | 1 | $23 |
| Koelis Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Photocure Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,160
- Urology Instrumentation$4,000
- LYNPARZA$1,628
- Erleada$1,555
- PROVENGE$1,325
- UroLift$983
- Nubeqa$924
- JELMYTO$311
- ELIGARD$151
- ADSTILADRIN$131
- Prolaris$126
- XTANDI$119
How this compares
$18,816 in reported general payments places this provider in the 95th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 124 | $2,041,861 |
| ErleadaApalutamide | 23 | $360,330 |
| OrgovyxRelugolix | 78 | $343,519 |
| MyrbetriqMirabegron | 39 | $40,050 |
| Tamsulosin Hcl | 371 | $6,579 |
| Oxybutynin Chloride ErOxybutynin Chloride | 55 | $2,159 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 214 | $2,132 |
| Finasteride | 88 | $1,637 |
| Cefpodoxime Proxetil | 66 | $1,107 |
| Methenamine Hippurate | 20 | $1,039 |
| Duloxetine Hcl | 32 | $1,029 |
| Pentoxifylline | 23 | $874 |
| Bicalutamide | 15 | $841 |
| Dutasteride | 17 | $361 |
| Cephalexin | 39 | $358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $68 | $2,081,911163 claims |
| Johnson & JohnsonErleada | $243 | $360,33023 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $44 | $343,51978 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 urology providers in Delaware.
Other urology in Wilmington
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Bruce BengeWilmington$5K
- Alice WangWilmington$4K
- Keara DecotiisWilmington$3K
- Mohamed IsmailWilmington$3K
- David CozzolinoWilmington$2K
- Mona YezdaniWilmington$2K
- Steven TerranovaWilmington$2K
- Andrew GlickWilmington$748
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.